Cargando…

The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast.

Recurrence and survival rates were studied in 175 women with breast cancer who, until the development of recurrent disease, received no treatment other than a modified radical (Patey) mastectomy, and in whom the oestrogen (REc) and progesterone (RPc) receptor content of the primary tumour was measur...

Descripción completa

Detalles Bibliográficos
Autores principales: Howat, J. M., Harris, M., Swindell, R., Barnes, D. M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1985
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977040/
https://www.ncbi.nlm.nih.gov/pubmed/3966982
_version_ 1782135177848291328
author Howat, J. M.
Harris, M.
Swindell, R.
Barnes, D. M.
author_facet Howat, J. M.
Harris, M.
Swindell, R.
Barnes, D. M.
author_sort Howat, J. M.
collection PubMed
description Recurrence and survival rates were studied in 175 women with breast cancer who, until the development of recurrent disease, received no treatment other than a modified radical (Patey) mastectomy, and in whom the oestrogen (REc) and progesterone (RPc) receptor content of the primary tumour was measured. At the time of first relapse most patients received endocrine therapy. At a minimum follow-up of 58 months post menopausal patients who possessed REc had an increased relapse-free survival (RFS) (P = 0.02). When examined by node status patients with 1-3 axillary nodes containing tumour also had an improvement in RFS (P = 0.02). There was no benefit for node-negative or premenopausal patients. In 163 patients in whom RPc was measured, RFS was unaffected by the possession of this receptor regardless of the degree of node involvement or menopausal status. Patients with REc had a significantly longer survival following mastectomy than patients without it (P = 0.006). This was most marked in post-menopausal (P = 0.003) and node-positive (P = 0.03) patients. Survival following mastectomy was also increased in patients possessing RPc (P = 0.04) and again was most marked for post-menopausal patients (P = 0.01), although no difference could be identified within node subgroups. There were significant differences in the post-relapse survival of REc and RPc positive and negative patients (REc P = 0.03, RPc P = 0.001). Patients with both receptors survived approximately 37 months longer than their receptor-negative counterparts. This study failed to confirm that the measurement of REc and RPc can reliably predict early relapse in breast cancer. The greater overall survival of receptor-positive patients is mainly due to an increase in survival following relapse. This may reflect the response of receptor-positive tumours to endocrine therapy given for recurrent disease.
format Text
id pubmed-1977040
institution National Center for Biotechnology Information
language English
publishDate 1985
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19770402009-09-10 The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast. Howat, J. M. Harris, M. Swindell, R. Barnes, D. M. Br J Cancer Research Article Recurrence and survival rates were studied in 175 women with breast cancer who, until the development of recurrent disease, received no treatment other than a modified radical (Patey) mastectomy, and in whom the oestrogen (REc) and progesterone (RPc) receptor content of the primary tumour was measured. At the time of first relapse most patients received endocrine therapy. At a minimum follow-up of 58 months post menopausal patients who possessed REc had an increased relapse-free survival (RFS) (P = 0.02). When examined by node status patients with 1-3 axillary nodes containing tumour also had an improvement in RFS (P = 0.02). There was no benefit for node-negative or premenopausal patients. In 163 patients in whom RPc was measured, RFS was unaffected by the possession of this receptor regardless of the degree of node involvement or menopausal status. Patients with REc had a significantly longer survival following mastectomy than patients without it (P = 0.006). This was most marked in post-menopausal (P = 0.003) and node-positive (P = 0.03) patients. Survival following mastectomy was also increased in patients possessing RPc (P = 0.04) and again was most marked for post-menopausal patients (P = 0.01), although no difference could be identified within node subgroups. There were significant differences in the post-relapse survival of REc and RPc positive and negative patients (REc P = 0.03, RPc P = 0.001). Patients with both receptors survived approximately 37 months longer than their receptor-negative counterparts. This study failed to confirm that the measurement of REc and RPc can reliably predict early relapse in breast cancer. The greater overall survival of receptor-positive patients is mainly due to an increase in survival following relapse. This may reflect the response of receptor-positive tumours to endocrine therapy given for recurrent disease. Nature Publishing Group 1985-02 /pmc/articles/PMC1977040/ /pubmed/3966982 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Howat, J. M.
Harris, M.
Swindell, R.
Barnes, D. M.
The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast.
title The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast.
title_full The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast.
title_fullStr The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast.
title_full_unstemmed The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast.
title_short The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast.
title_sort effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977040/
https://www.ncbi.nlm.nih.gov/pubmed/3966982
work_keys_str_mv AT howatjm theeffectofoestrogenandprogesteronereceptorsonrecurrenceandsurvivalinpatientswithcarcinomaofthebreast
AT harrism theeffectofoestrogenandprogesteronereceptorsonrecurrenceandsurvivalinpatientswithcarcinomaofthebreast
AT swindellr theeffectofoestrogenandprogesteronereceptorsonrecurrenceandsurvivalinpatientswithcarcinomaofthebreast
AT barnesdm theeffectofoestrogenandprogesteronereceptorsonrecurrenceandsurvivalinpatientswithcarcinomaofthebreast
AT howatjm effectofoestrogenandprogesteronereceptorsonrecurrenceandsurvivalinpatientswithcarcinomaofthebreast
AT harrism effectofoestrogenandprogesteronereceptorsonrecurrenceandsurvivalinpatientswithcarcinomaofthebreast
AT swindellr effectofoestrogenandprogesteronereceptorsonrecurrenceandsurvivalinpatientswithcarcinomaofthebreast
AT barnesdm effectofoestrogenandprogesteronereceptorsonrecurrenceandsurvivalinpatientswithcarcinomaofthebreast